Rituximab likely raises risk of hospital death in COVID-19 patients
December 2, 2021
In a retrospective study of hospitalized COVID-19 patients, “only 1 of 303 drugs examined, rituximab, was associated with an increased risk of in-hospital death ... both when used for rheumatologic as well as for cancer therapy.”
Tocilizumab shortage continues as pandemic wears on
August 19, 2021
Emergency use authorization of tocilizumab for COVID-19 has led to a global shortage, but supplies for rheumatoid arthritis and other inflammatory conditions are faring better – for now.
Arthritis drug may curb myocardial damage in acute STEMI
April 13, 2021
Tocilizumab appears to improve myocardial salvage by helping tamp down the inflammatory overshoot that occurs during infarction and reperfusion.
Rheumatologic disease activity an important influencer of COVID-19 death risk
February 5, 2021
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from COVID-19.
Arthritis drugs ‘impressive’ for severe COVID but not ‘magic cure’
January 15, 2021
U.S. and U.K. experts weigh in on research that compares monoclonal antibody therapies with usual care for people critically ill with COVID-19.
Baricitinib combo for COVID-19 accelerates recovery, study shows
December 14, 2020
The combination is intended for patients who need supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.
COVID-19 risks in rheumatic disease remain unclear
November 7, 2020
Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more encouraging news for people living with rheumatic disease.
COVID-19–related HCQ shortages affected rheumatology patients worldwide
November 6, 2020
Data from the Global Rheumatology Alliance Patient Experience Survey presented at ACR Convergence 2020 demonstrate that the severity of shortages differed widely across the globe.
Even a few days of steroids may be risky, new study suggests
July 9, 2020
A retrospective study of more than 2.6 million Taiwanese adults echoes findings from a 2017 cohort study of more than 1.5 million U.S. adults.
ACIP approves flu vaccine recommendations for 2020-2021
June 25, 2020
Next season’s vaccination options include new high-dose quadrivalent vaccines for seniors.